On December 29, at the Launch of GV-971 Global Strategy and 1st Gut-Brian Axis Forum, hosted by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and undertaken by Green Valley Pharmaceuticals, Yang Baofeng, Vice Chairman of the Chinese Medical Association and Academician of the Chinese Academy of Engineering, pointed out that as AD remains a conundrum for the global medical community, it’s very commendable for China to earn a place in the field, especially by securing an original achievement after no new AD drug was approved in the past 17 years.